Analyst Ratings for Intellia Therapeutics
Portfolio Pulse from Benzinga Insights
Intellia Therapeutics (NASDAQ:NTLA) received 4 analyst ratings in the last quarter, with 1 bullish and 3 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The average price target is $80.75, which is significantly higher than the current price of $23.64, suggesting a substantial upside. However, this target represents a 31.28% decrease from the previous target of $117.50.
November 10, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics has a positive outlook from analysts with an average price target of $80.75, indicating a potential upside from the current price of $23.64.
The positive analyst ratings and the substantial upside implied by the average price target suggest a bullish sentiment for Intellia Therapeutics in the short term. However, the decrease in the average price target may indicate some caution, possibly due to revised expectations or market conditions. The confidence score is not at the maximum due to the inherent uncertainty in analyst predictions and the recent decrease in the price target.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100